G2GBIO, Inc.
KKRX:45616049,700.00
KRW
+8,500.00
(+20.63%)
ISIN
KR7456160001
Return %
Stock
S&P 500
1Y
-17.03
13.14
3Y
- -
80.78
5Y
- -
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Hee-Yong Lee
- Full Time Employees
- 48
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Cheongju-si South Korea
- IPO Date
- Aug 14, 2025
- Website
- g2gbio.com
- Similar Companies
- Business
- G2GBIO, Inc. is a South Korea-based biopharmaceutical company specializing in the development of long-acting sustained-release injectable therapeutics utilizing proprietary microsphere drug delivery platform technologies. The company operates through two primary business segments: Pharmaceutical Pipeline Development and Contract Development and Manufacturing Organization (CDMO) Services. G2GBIO develops sustained-release formulations engineered to extend drug efficacy from one week up to six months, significantly improving patient compliance and therapeutic outcomes across central nervous system disorders, metabolic diseases, chronic pain, and veterinary medicine. Its core technology platforms and product pipeline encompass: InnoLAMP (Innovative Long-Acting MicroParticle), a proprietary drug delivery system that encapsulates small molecules and peptide drugs into uniform biodegradable polymer microspheres for controlled release; InteLAMP, an advanced formulation platform engineered for specialized macromolecule delivery; GB-5001 and GB-5001A, long-acting monthly injectable formulations of donepezil indicated for the treatment of Alzheimer's disease and cognitive disorders; GB-7001, a sustained-release formulation of semaglutide administered at one-month to three-month intervals for the management of type 2 diabetes, obesity, and related metabolic conditions; GB-6002, a sustained-release ropivacaine injectable designed for long-lasting post-operative surgical pain management; GB-5021 and GB-5023, extended-release therapeutic candidates under development for psychiatric disorders including schizophrenia; and specialized long-acting veterinary therapeutics targeting animal pain management and chronic conditions. In addition to its proprietary pipeline, G2GBIO provides contract development, formulation screening, analytical testing, and good manufacturing practice (GMP) production services to domestic and multinational pharmaceutical partners from its dedicated manufacturing facility located in Osong, South Korea. In recent strategic developments, G2GBIO executed its initial public offering and listed its common shares on the KOSDAQ market under the ticker symbol 456160. The company entered into a collaborative formulation development agreement with Boehringer Ingelheim to co-develop long-acting peptide injectable candidates using the InnoLAMP platform. Furthermore, G2GBIO expanded its global commercial engagements through Master Services Agreements with multinational pharmaceutical corporations for CDMO projects, advanced clinical development for its Alzheimer's candidate GB-5001 following the completion of Phase 1 clinical studies, and progressed preclinical evaluation and formulation optimization for its extended-release semaglutide candidate GB-7001. Founded in 2017, G2GBIO, Inc. is headquartered in Cheongju-si, Chungcheongbuk-do, South Korea, and serves global biopharmaceutical markets across Asia, North America, and Europe.